secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001564590-22-001402
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind partner UT's Tyvaso DPI NDA accepted for FDA Class 1 review; goal Feb 2022
--------------------------------------------------------------------------------

- FDA accepted United Therapeutics' resubmitted NDA for Tyvaso DPI as a Class 1 response.
- User fee goal date set for February 2022.
- UT previously received a Complete Response Letter in October 2021 for the NDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000156459022001402/0001564590-22-001402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000156459022001402/mnkd-8k_20220118.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-001402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer